Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $15.67.

Several equities research analysts recently weighed in on OCUL shares. TD Cowen lowered Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 21st. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Ocular Therapeutix in a report on Thursday, August 1st. Robert W. Baird decreased their price target on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Friday, June 21st.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Great Point Partners LLC purchased a new stake in Ocular Therapeutix during the 4th quarter valued at $3,122,000. Artia Global Partners LP purchased a new stake in Ocular Therapeutix during the fourth quarter valued at $1,962,000. Deltec Asset Management LLC lifted its holdings in Ocular Therapeutix by 9.6% in the second quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company’s stock valued at $17,717,000 after acquiring an additional 226,181 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Ocular Therapeutix by 1,142.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 662,672 shares of the biopharmaceutical company’s stock worth $6,031,000 after purchasing an additional 609,328 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Ocular Therapeutix by 41.4% during the 1st quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock valued at $65,840,000 after purchasing an additional 2,117,029 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Stock Down 0.1 %

Shares of Ocular Therapeutix stock opened at $9.04 on Friday. The company’s fifty day simple moving average is $8.41 and its two-hundred day simple moving average is $7.48. Ocular Therapeutix has a 12-month low of $2.00 and a 12-month high of $11.31. The company has a current ratio of 16.64, a quick ratio of 16.55 and a debt-to-equity ratio of 0.18. The company has a market cap of $1.40 billion, a P/E ratio of -6.70 and a beta of 1.28.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). The company had revenue of $16.40 million during the quarter, compared to the consensus estimate of $15.85 million. Ocular Therapeutix had a negative return on equity of 52.75% and a negative net margin of 226.46%. Ocular Therapeutix’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.27) earnings per share. Research analysts anticipate that Ocular Therapeutix will post -1.02 EPS for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.